We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still's Disease and Active Articular Manifestation Responding to Canakinumab.
- Authors
Ghannam, Khetam; Zernicke, Jan; Kedor, Claudia; Listing, Joachim; Burmester, Gerd-R.; Foell, Dirk; Feist, Eugen
- Abstract
Adult-onset Still's disease (AOSD) is a systemic auto-inflammatory disease characterized by the presence of immunologically mediated inflammation and deficient resolution of inflammation. Canakinumab is an approved IL-1β inhibitor in the treatment of AOSD with a balanced efficacy and safety profile. Since inflammatory cytokines play a major role in the pathogenesis of AOSD, we investigated the effects of canakinumab on the cytokine profile of AOSD patients from a randomized controlled trial. Multiplex analysis and ELISA were used to test the concentrations of several cytokines at three time points—week 0 (baseline), week 1 and week 4—in two patient groups—placebo and canakinumab. Two-way repeated-measures analysis of variance revealed a significant temporal effect on the concentrations of MRP 8/14, S100A12, IL-6 and IL-18 with a significant decrease at week 4 in the canakinumab group exclusively. Comparing responders with non-responders to canakinumab showed a significant decrease in MRP 8/14, IL-1RA, IL-18 and IL-6 in responders at week 4, while S100A12 levels decreased significantly in responders and non-responders. In summary, canakinumab showed a striking effect on the cytokine profile in patients with AOSD, exhibiting a clear association with clinical response.
- Subjects
STILL'S disease; CYTOKINES; TWO-way analysis of variance
- Publication
Journal of Clinical Medicine, 2021, Vol 10, Issue 19, p4400
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm10194400